These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36467355)

  • 21. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Sequentially Evolved
    Zhu VW; Nagasaka M; Madison R; Schrock AB; Cui J; Ou SI
    JTO Clin Res Rep; 2021 Jan; 2(1):100116. PubMed ID: 34589977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel
    Shen G; Du Y; Shen J; Zhang J; Xia X; Huang M; Shen W
    Onco Targets Ther; 2021; 14():5471-5475. PubMed ID: 34992382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
    Tan DS; Thomas M; Kim DW; Szpakowski S; Urban P; Mehra R; Chow LQM; Sharma S; Solomon BJ; Felip E; Camidge DR; Vansteenkiste J; Petruzzelli L; Pantano S; Shaw AT
    Lung Cancer; 2022 Jan; 163():7-13. PubMed ID: 34890832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare
    Li Y; Duan P; Guan Y; Chen Q; Grenda A; Christopoulos P; Denis MG; Guo Q
    Transl Lung Cancer Res; 2022 Jan; 11(1):100-110. PubMed ID: 35242631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case report: Two novel
    Liao S; Sun H; Wu J; Lu H; Fang Y; Wang Y; Liao W
    Front Oncol; 2022; 12():916315. PubMed ID: 35941871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
    Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
    Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durable clinical response to ALK tyrosine kinase inhibitors in
    Hu H; Dai H; Ding L
    Transl Cancer Res; 2022 Aug; 11(8):2967-2972. PubMed ID: 36093526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring
    Xiao Z; Huang X; Xie B; Xie W; Huang M; Lin L
    Onco Targets Ther; 2020; 13():4591-4595. PubMed ID: 32547089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
    Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
    Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
    Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
    Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
    Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
    Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
    Yamamoto K; Toyokawa G; Kozuma Y; Shoji F; Yamazaki K; Takeo S
    Thorac Cancer; 2021 Jun; 12(11):1761-1764. PubMed ID: 33939293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
    Shen J; Meng Y; Wang K; Gao M; Du J; Wang J; Li Z; Zuo D; Wu Y
    Cell Signal; 2022 Apr; 92():110264. PubMed ID: 35085771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.